Ricerca avanzata

Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2001 Marzo;43(1) > Panminerva Medica 2001 Marzo;43(1):15-9

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOPANMINERVA MEDICA

Rivista di Medicina Interna

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6

Periodicità: Trimestrale

ISSN 0031-0808

Online ISSN 1827-1898

 

Panminerva Medica 2001 Marzo;43(1):15-9

 ORIGINAL ARTICLES

Gemcitabine as single agent therapy in advanced non small cell lung cancer and quality of life in the elderly

Bianco V., Di Girolamo B., Pignatelli E., Speranza I., Florio G., Gemma D., Girolami M., Vietri F., Marchei P.

From the Department of Experimental Medicine and Pathology Medical Oncology Unit Umberto I Polyclinic University “La Sapienza”, Roma, Italy

Background. The aim of ­this ­study is to ­test the effi­cacy of gem­cit­a­bine as ­single ­agent ­therapy in ­advanced non-­small ­cell ­lung ­cancer in the eld­erly by the eval­u­a­tion of the clin­ical ­response, the sur­vival ­increase and the ­quality of ­life.
Methods. Nineteen ­patients (age >65 ­years) ­with a PS >2, ­bearing an ­advanced non-­small ­cell ­lung ­cancer (IIIb-IV) not ­treated ­with chem­o­therapy ­before, ­were ­charged ­between December 1996 and December 1998. Sixteen ­patients ­were ­treated ­with gem­cit­a­bine at the ­dose of 1000 mg/mq 1-8-15 ­every 28 ­days. CT ­scan, X-rays and skel­etal scin­tig­raphy ­were ­used in the eval­u­a­tion of the ther­a­peutic ­response. The tox­icity was esti­mated by fol­lowing WHO ­indexes. The ­quality of ­life and the mod­ifi­ca­tion of the spe­cific symp­toms ­were esti­mated by par­tic­ular ­tests (Spitzer Index, ­IADL, ­EORTC-LC13).
Results. One com­plete ­response (6%), 4 par­tial ­responses (25%), 7 ­cases of ill­ness sta­bil­iza­tion (43%), 4 ­cases of ill­ness pro­gres­sion, ­were ­shown. One ­year of sur­vival was ­found in 43% of ­cases ­with a 14 ­week of ther­a­peutic ­response and a ­global sur­vival ­ratio of 12.4 ­weeks. Only 2 ­cases (12.5) of ­medium ­grade G3-leu­co­penia ­were ­found. All ­patients ­improved ­their ­quality of ­life (­IADL and Spitzer ­indexes) ­with reduc­tion of symp­toms, (­EORTC-LC13) and ­increase of ­self-­agin and rela­tion­ships.
Conclusions. The effec­tive­ness of gem­cit­a­bine as ­single ­agent ­therapy as not yet ­been ­tested due to the ­scanty ­number of ­patients, nev­er­the­less it ­must be con­sid­ered in rela­tion to the improve­ment of the ­patient’s ­quality of ­life.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina